2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.31 Decoding First-line strategies in EGFR-mutated NSCLC: A Computational Analysis of FLAURA2 vs. MARIPOSA

PP01.31 Decoding First-line strategies in EGFR-mutated NSCLC: A Computational Analysis of FLAURA2 vs. MARIPOSA

Pdf Summary

This study aims to evaluate the efficacy of two first-line treatment strategies, FLAURA2 and MARIPOSA, for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The analysis focuses on comparing the combination therapies of osimertinib with chemotherapy versus amivantamab with lazertinib. Using a computational method, Individual Patient Data (IPD) was reconstructed from Kaplan-Meier survival plots to assess progression-free survival (PFS) and overall survival (OS) for patients. <br /><br />The results indicate that patients receiving osimertinib-chemotherapy had a superior median PFS of 26.1 months compared to 22.6 months in the amivantamab-lazertinib group. The hazard ratio was 0.79, suggesting osimertinib-chemotherapy is more effective (p=0.043). OS data is still not fully mature, as analyses at the 12- and 24-month benchmarks showed no statistically significant differences between the two therapies.<br /><br />Importantly, osimertinib-chemotherapy showed notable efficacy in high-risk subgroups. Patients with central nervous system (CNS) metastases had significantly improved 12-month and 24-month survival rates compared to amivantamab-lazertinib. Additionally, patients with TP53 co-mutations demonstrated better survival rates with osimertinib-chemotherapy at both 12- and 24-month milestones.<br /><br />The study concludes that osimertinib-chemotherapy provides superior efficacy, especially for high-risk patients with EGFR-mutated NSCLC, compared to the amivantamab-lazertinib regimen. Nevertheless, the authors recommend further head-to-head prospective studies to confirm the most effective frontline treatment strategy for this patient group.

Asset Subtitle

Sanad Alhushki

Keywords

EGFR-mutated NSCLC

FLAURA2

MARIPOSA

osimertinib

chemotherapy

amivantamab

lazertinib

progression-free survival

central nervous system metastases

TP53 co-mutations